Benzinga | Aug 19, 2021 07:32AM EDT

Adamis Pharmaceuticals Highlights NIH Article 'Tempol: A Potential Home Treatment for COVID-19'

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today highlighted that the NIH has identified Tempol as a potential home treatment for COVID-19 (TEMPOL: A Potential Home Treatment for COVID-19 | NIH COVID-19 Research). The NIH news stated that, "This treatment would likely prevent severe disease." The article went on to describe how Tempol could reduce COVID-19 symptoms by calming inflammation, protecting organs from damage, and decreasing the clumping of platelets. The U.S. Food & Drug Administration (FDA) has given the go-ahead to Adamis Pharmaceuticals to conduct a clinical study using Tempol as an at home treatment to prevent disease progression and thereby releasing the burden of COVID-19 on the healthcare system. Adamis plans to initiate the study shortly.